Clinical Trial Update: Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT [Phase 2]

View source ↗

Summary

Phase 2 trial update on natural killer (NK) cell-enriched dendritic cell vaccines with or without a RLR9 agonist (DUK-CPG-001) from donors after allogeneic stem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Malignancies
• Myeloid Malignancies

Drugs mentioned

• DUK-CPG-001

Snippet

Sponsor: Cristina Gasparetto | Conditions: Myeloid Malignancies, Lymphoid Malignancies | Phase 2 | Status: UNKNOWN | Results posted: 2024-02-20